No. BPD-E will not be publicly reporting for MY 2026; NCQA will allow voluntary ECDS reporting for BPD-E. The administrative and hybrid version of the BPD measure will continue to be publicly reported for MY 2026.
HEDIS MY 2026
FAQ Directory: HEDIS
Filter Results
9.15.2025 Public Reporting of the Blood Pressure Control for Patients With Diabetes (BPD-E) Measure Will the BPD-E measure which transitioned to ECDS reporting in MY 2026, be publicly reported for MY 2026?
9.15.2025 Public Reporting of Lead Screening in Children (LSC-E), Statin Therapy for Patients With Cardiovascular Disease (SPC-E), and Statin Therapy for Patients With Diabetes (SPD-E) Measures Will the LSC-E, SPC-E and SPD-E measures, which transitioned to ECDS reporting in MY 2026, be publicly reported for MY 2026?
9.15.2025 Appendices Were some appendices removed from the Volume 2 publication?
Yes. Some appendices were removed from the publication. This approach for HEDIS MY 2026 reduced redundancy, considered the broader product changes and whether users might prefer to engage with information outside the publication.
For example, as an alternative to Appendix 2: Technical Considerations for New Measures, clinical guideline recommendations for each measure are included directly in the measure specifications. NCQA also updated the State of Health Care Quality Report to reflect the latest HEDIS measure set release, including new measures for MY 2026. The State of Health Care Quality Report is publicly available at NCQA.org.
NCQA is committed to supporting stakeholders who use HEDIS, and we welcome feedback as we continue to evolve HEDIS.
HEDIS MY 2026
9.15.2025 PCS Questions Do answers from the Policy Clarification Support system have an expiration date?
7.15.2025 Multiple BIRADS Assessments for Documented Assessment After Mammogram (DBM-E) If multiple distinct mammograms are identified on the same date of service, does a single BI-RADS score within 14 days of each mammogram make the member compliant for all mammograms?
No. Each mammogram requires a unique BIRADS assessment (e.g., two mammograms need two separate BIRADS to meet numerator criteria). A single documented BIRADS assessment dated on or within 14 days (15 days total) of multiple mammography episodes does not meet criteria for multiple denominator events.
DBM-E sample and test decks have been updated and re-posted. If you already received a status of “pass” for a DBM-E test deck, the status has been re-set and you must run the updated deck to certify. The deadline to certify the measure will be extended to July 31 so organizations can accommodate this update.
HEDIS MY 2025
7.15.2025 Deduplication of Mammography Episodes on the Same Date of Service for Documented Assessment After Mammogram (DBM-E) If there is more than one eligible mammography episode on the same date of service, does that count as a single denominator event?
It is up to the organization to ensure that multiple mammograph episodes are the same event if they occur on the same date of service. HEDIS measure certification assumes events on the same day are different mammograms. If evidence shows the mammography episodes are the same, count only one. Organizations should develop their own methods and apply them consistently when reporting.
HEDIS MY 2025
7.15.2025 Multiple BIRADS assessments for Follow-Up After Abnormal Mammogram Assessment (FMA-E) Can one follow-up event meet criteria for multiple BIRADS assessments?
Yes. One follow-up event may meet criteria for multiple BIRADS assessments. Each BIRADS assessment counts as separate denominator events, and requires the appropriate follow-up to count toward the numerator. However, one breast biopsy may meet criteria for multiple high-risk BIRADS assessments, and one mammogram or ultrasound may meet criteria for multiple inconclusive BIRADS assessments.
HEDIS MY 2025
6.13.2025 TotalKnown Data Element for Language Diversity of Membership (LDM) Is the TotalKnown data element in Table LDM-A-1/2/3 and Table LDM-B-1/2/3 a calculated data element?
6.13.2025 Direct reference code POS 81 for Adult Immunization Status (AIS-E) POS code 81 is included in the AIS-E measure specification but is not included in the Direct Reference Code tab of the VSD. Should the code be used when reporting Adult Immunization Status for MY 2025?
Yes. As described in Numerator 5—Immunization Status: Hepatitis B, use POS code 81 to exclude laboratory claims when identifying members with a history of hepatitis B illness. POS code 81 was mistakenly omitted from the Direct Reference Code tab of the VSD. Because the information needed for reporting is in the measure specification, NCQA does not intend to reissue the VSD.
HEDIS MY 2025
5.15.2025 Medication List in Deprescribing of Benzodiazepines in Older Adults (DBO) In the MY 2025 Medication List Directory, three codes (NDC codes 00378027701, 00378027705; RxNorm code 856792) are included in both the Chlordiazepoxide 10 MG Medications List and the Chlordiazepoxide 25 MG Medications List. Should the codes be included in both lists?
No. The codes are for “amitriptyline hydrochloride 25 MG/chlordiazepoxide 10 MG Oral Tablet.” They belong only in the Chlordiazepoxide 10 MG Medications List. NCQA re-released the MY 2025 Medication List directory on May 15, 2025, to incorporate this update. NCQA’s Measure Certification program confirmed that certification organizations deleted the codes from the Chlordiazepoxide 25 MG Medications List. No changes to the current process are necessary.
HEDIS MY 2025
